Skip to content
DataLookout
Menu

NCT07295496

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jun 7, 2026 to Aug 6, 2026
    • Study completion date changed from estimate of Jun 7, 2026 to Sep 28, 2026
    • Secondary endpoints: details revised at 4 of 6 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 12 week

Secondary (6)

Immunogenic outcome
AUC
Cmax
CL or CL/F
V or V/F
Show 1 moreShow less
t1/2

Arms and interventions

PlaceboPlacebo comparator

IBI3011 placebo group

IBI3011Experimental

IBI3011 group

Drugs: IBI3011, IBI3011 Placebo

Sites

1 site in 1 country

  • The First Affiliated Hospital of Soochow UniversitySuzhou, Jiangsu, China